45 recruiting, 23 not yet recruiting, 20 unknown, 17 completed. 130 Phase 2, 14 Phase 1, 5 Phase 3.
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer Biospecimen Collection, Computed Tomography, Immunotherapy - Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 2 | Not yet recruiting | NRG Oncology | 138 | 2026-12-18 | 2026-09-23 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. FMT combined with chemotherapy plus immunotherapy, Chemotherapy+Immunotherapy - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2026-11-01 | 2026-10-02 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 164 | 2026-10-14 | 2026-11-03 |
| Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer Personalized ultrafractionated stereotactic adaptive radiotherapy, Immunotherapy, Target Therapy - Colo-rectal Cancer | Phase 2 | Not yet recruiting | West China Hospital | 32 | 2026-10-09 | 2026-10-29 |
| Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy - Hepatocellular Carcinoma | Phase 2 | Recruiting | Anhui Provincial Hospital | 60 | 2026-09-16 | 2026-09-21 |
| TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study. TACE combined with thermal ablation, Targeted Therapy, Immunotherapy - Gastric Cancer With Liver Metastases | Phase 2 | Not yet recruiting | Shandong Provincial Hospital | 40 | 2026-08-01 | 2026-05-22 |
| Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC Short-course radiotherapy, Long-course radiotherapy, Immunotherapy - Locally Advanced Rectal Adenocarcinoma, Neoadjuvant Chemoradiation | Phase 2 / Phase 3 | Not yet recruiting | Beijing Friendship Hospital | 342 | 2026-07-15 | 2026-06-17 |
| Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) Combination therapy with chemotherapy and immunotherapy, Surgery - ESCC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 200 | 2026-06-01 | 2026-05-13 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma Chemotherapy, Targeted Systemic Therapy, Immunotherapy - Esophageal Cancer, Gastric (Stomach) Cancer | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 290 | 2026-04-29 | 2026-09-10 |
| NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NALIRIFOX+Adebrelimab, PULSAR - Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | West China Hospital | 55 | 2026-04-01 | 2026-05-19 |
| Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy - Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II | Phase 2 | Not yet recruiting | Beijing Friendship Hospital | 19 | 2026-03-01 | 2026-02-11 |
| Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC Experimental: short-course radiotherapy and immunotherapy, Chemoradiotherapy - Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 128 | 2026-03-01 | 2026-07-31 |
| Tolerance Results and Immune Mechanisms in Cow´s Milk and/or Hen´s Egg Allergic Children Following Natural Evolution or Oral Immunotherapy Oral Immunotherapy, Allergenic food avoidance - Food Allergy in Children | Phase 1 / Phase 2 | Recruiting | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 68 | 2026-02-18 | 2026-02-27 |
| A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors. Interventional, Targeted Therapy (anti-VEGF), Immunotherapy + Targeted Therapy - Pancreatic Cancer Liver Metastases, Immunotherapy-naive | Phase 2 | Not yet recruiting | Shandong Provincial Hospital | 38 | 2026-02-01 | 2026-01-12 |
| Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma Immunotherapy, Induction chemotherapy, D2 radical gastrectomy - Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 15 | 2026-01-31 | 2026-01-07 |
| Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma TACE (transarterial chemoembolization) combined with targeted/immunotherapy - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Wei Zhang | 27 | 2025-12-30 | 2025-09-04 |
Showing 20 of 130. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (21) · Carcinoma, Hepatocellular (13) · Melanoma (9) · Squamous Cell Carcinoma of Head and Neck (8) · Lung Neoplasms (7) · Esophageal Neoplasms (5) · Esophageal Squamous Cell Carcinoma (5) · Neoplasm Metastasis (5) · Neoplasms (5) · Rectal Neoplasms (4) · Cholangiocarcinoma (3) · Head and Neck Neoplasms (3) · Pancreatic Neoplasms (3) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Uterine Cervical Neoplasms (3)
H. Lee Moffitt Cancer Center and Research Institute (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · Sun Yat-sen University (5) · West China Hospital (5) · Shanghai Chest Hospital (4) · Zhejiang University (4) · Fudan University (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Zhejiang Cancer Hospital (3) · Anhui Provincial Hospital (2) · Beijing Friendship Hospital (2) · Melanoma Institute Australia (2) · Obstetrics & Gynecology Hospital of Fudan University (2) · Shandong Cancer Hospital and Institute (2) · Shandong Provincial Hospital (2)
China (63) · United States (28) · Germany (5) · Spain (5) · France (4) · Netherlands (3) · Australia (2) · Canada (2) · Italy (2) · Sweden (2) · Switzerland (2) · Belgium (1) · Brazil (1) · Czechia (1) · India (1)
Alberto Chiappori, M.D. (2) · Himanshu Nagar, M.D. (2) · Hui Liu, Professor (2) · Liangrong Shi, M.D. (2) · Wen Yu, M.D (2) · You Lu (2) · Adam Ostrowski, MD (1) · Adriana Rossi, M.D. (1) · Aiwu Ruth He, MD PhD (1) · Alex Menzies (1) · Angela Hong (1) · Annika Hollsing, MD, PhD (1) · Beau Toskich, MD (1) · Brandon Triplett, MD (1) · Daniel Indelicato, M.D. (1)
PMID 37280366, PMID 19515503, PMID 20842054, PMID 21561347, PMID 22658128, PMID 22867890, PMID 23127803, PMID 23775348, PMID 24131140, PMID 25601342, PMID 29454091, PMID 29556198, PMID 30207593, PMID 31212833, PMID 31331945, PMID 32366856, PMID 32577817, PMID 32671834, PMID 32738599, PMID 32827353, PMID 33294918, PMID 33438349, PMID 33476803, PMID 33794306, PMID 34376578, PMID 34377028, PMID 34439389, PMID 34663254, PMID 34665942, PMID 34726575, PMID 34799585, PMID 34844976, PMID 35135810, PMID 35543554, PMID 36757445, PMID 36974574, PMID 37199326, PMID 37272513, PMID 37459862, PMID 37708904, PMID 37820884, PMID 37937444, PMID 38051328, PMID 38572751, PMID 38589494, PMID 38641773, PMID 38964333, PMID 39008192, PMID 39089313, PMID 39276114
P30CA012197 (2), P30CA014089 (1), U10CA180868 (1)